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Toll like receptors (TLRs) are a family of pattern recognition receptors that play a central
role in the innate immune response. These receptors are expressed on a wide variety of
immune and non-immune cells, and they help shape the immune response to infection
and injury through the recognition of pathogen-associated molecular patterns (PAMPs)
as well as endogenous damage-associated molecular patterns (DAMPs). Accumulating
evidence suggests that, in addition to regulating mature effector immune cells, TLRs
can influence the immune response from the level of the hematopoietic stem cell
(HSC). HSCs express TLRs, and exposure to TLR ligands influences the cycling,
differentiation, and function of HSCs, with chronic TLR stimulation leading to impairment
of normal HSC repopulating activity. Moreover, enhanced TLR expression and signaling
is associated with myelodysplastic syndromes (MDS), a heterogenous group of HSC
disorders characterized by ineffective hematopoiesis and a high risk of transformation
to acute leukemias. In this review, we will discuss the role of TLR signaling in the
pathogenesis of MDS, focusing on the known direct and indirect effects of this type of
signaling on HSCs, themechanisms of TLR signaling upregulation inMDS, the changes in
TLR expression with disease progression, and the therapeutic implications for modulating
TLR signaling in the treatment of MDS.
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INTRODUCTION
The TLRs are a family of pattern recognition receptors that recognize foreign pathogen-associated
molecular patterns (PAMPs) as well as endogenous byproducts of cellular damage (so called
“damage-associated molecular patterns,” or DAMPs) (1, 2), and play a central role in the innate
immune response to infections and tissue injury (3–6). TLR signaling regulates not only mature
effector cells of the immune system, but also influences hematopoietic stem cells (HSCs) through
both cell-autonomous and cell non-autonomous mechanisms (7–9). Furthermore, chronic TLR
signaling can impair normal HSC function (10). In patients with myelodysplastic syndromes
(MDS), TLR signaling is enhanced via a combination of genetic and epigenetic events that influence
multiple components of the TLR signaling pathway. This enhanced signaling is particularly
notable in lower-risk MDS, and contributes to the marked cell death and ineffective hematopoiesis
characteristic of this disease (11). Here, we focus on the role of TLR signaling in MDS, highlighting
the mechanisms and implications of TLR upregulation, the differences between lower- and
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higher-risk disease, and the therapeutic opportunities for
targeting TLR signaling in the treatment of MDS.
TLR Signaling Regulates Hematopoietic
Stem and Progenitor Cell Function
The TLR family is comprised of 10 members in humans (TLR1-
TLR10) (5, 12–15), and 12 members in mouse (TLR1- TLR9,
and TLR11-TLR13) (16). TLRs are expressed on a variety of
hematopoietic cell types, such as dendritic cells, macrophages,
and lymphocytes, as well as non-hematopoietic cells such as
endothelium and epithelium (17–20), and can be found at the
cell surface (TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11)
or within endosomes (TLR3, TLR7, TLR8, and TLR9). TLRs
largely function as homodimers, with the exception of TLR2,
which heterodimerizes with either TLR1 or TLR6 (21–23).
With the exception of TLR3, which signals via the adaptor
TIR-domain-containing adaptor-inducing interferon-β (TRIF)
(24, 25), the TLRs utilize the intracellular signaling adaptor
myeloid differentiation primary response gene 88 (MyD88) (26).
MyD88 is recruited to activated TLRs, and this is followed
by recruitment of members of the serine-threonine kinase
interleukin-1 receptor-associated kinase (IRAK) family (IRAK4,
IRAK1, and IRAK2), forming the so-called “Myddosome.” (27–
29) Activated IRAK1 then promotes the activity of the E3
ubiquitin ligase tumor necrosis factor (TNF) R-associated factor
6 (TRAF6), which in turn activates transforming growth factor
beta-activated kinase 1 (TAK1) leading to stimulation of mitogen
activated protein kinase (MAPK) and nuclear factor k-light-
chain-enhancer of activated B cells (NF-kB) pathways and
the production of proinflammatory cytokines (30). Endosomal
TLRs (TLR3, TLR7, TLR8, and TLR9) act via the Myddosome
and TRAF6 to activate IFR7 and promote type I interferon
production. TRIF-dependent TLR signaling, utilized by TLR3
and, in part, TLR4, involves the binding of TRIF to TRAF3, which
then recruits TBK1 and IKKε thereby stimulating IRF3 and also
promoting the production of type I interferons (31–34).
In addition to regulating mature immune effector cells,
TLRs are expressed on more primitive hematopoietic stem
and progenitor cells (HSPCs) (7, 20, 35, 36), and even in
the absence of overt infection or injury, signaling through
the TLRs influences the differentiation, and function of
HSPCs. Proinflammatory signals, including TLR4-MyD88-NF-
kB activation, are required for HSC specification in both
zebrafish and mouse embryos (37, 38). Thereafter, TLR signaling
continues to regulate HSCs, as the bone marrow from mice
deficient in TLR signaling (Tlr2−/−, Tlr4−/−, Tlr9−/−, and
MyD88−/− mice) display enhanced repopulating activity in
competitive transplantation experiments (39, 40). Conversely,
chronic exposure to TLR ligands is associated with a loss
of normal HSC function. Persistent exposure of mice to the
TLR4 ligand LPS, for example, is associated with an expansion
of immunophenotypic HSCs, but a loss of HSC repopulating
function in transplantation experiments (10). Similarly, we
recently demonstrated that treatment of mice with the TLR1/2
ligand PAM3CSK4 expands immunophenotypic HSCs in both
the bone marrow and spleen, but reduces their repopulating
activity (8). Studies in chimeric mouse and in vitro models
suggest that these effects of TLR ligands on HSCs are mediated
by both direct (cell autonomous) and indirect (cell non-
autonomous) mechanisms. Supporting a direct effect of TLR
signaling on HSCs, for example, TLR stimulation via LPS or
PAM3CSK4 leads to proliferation and myeloid differentiation
of sorted HSPCs (Lineage- c-Kit+ Sca-1+ cells) in culture (7),
and purified HSPCs from wild-type mice transplanted into TLR-
deficient (Tlr2−/−, Tlr4−/−, or MyD88−/−) recipients (thus
minimizing indirect effects of TLR stimulation) differentiate into
macrophages upon treatment with TLR ligands (9). Takizawa
et al. (41) used chimericmice (Tlr4−/− andWT cells transplanted
into Tlr4−/− recipients) to show that LPS directly stimulates
HSC proliferation and impairs HSC self-renewal. Further, they
found that the LPS-induced loss of HSC self-renewal is TRIF-,
and not MyD88-, dependent, and is mediated by the production
of reactive oxygen species (ROS) and activation of p38 MAPK
(41). Zhang et al. (42) similarly showed that LPS-induced loss
HSC self-renewal is TRIF-dependent, and further highlighted
the differential effects of TRIF- and MYD88- dependent TLR4
signaling on HSPCs. While TRIF-mediated signaling accounts
for HSC expansion and loss of self-renewal in response to LPS,
MYD88- dependent signaling largely accounts for LPS-induced
myelosuppression via impaired differentiation and increased
death of myeloid progenitors (42). Our own studies using
chimeric mice treated with the TLR1/2 agonist PAM3CSK4
showed that while the loss of HSC function in response to
this type of stimulation is largely cell non-autonomous, direct
signaling does contribute to the expansion of immunophenotypic
HSCs (8). Thus, multiple TLRs can influence HSCs, both via
direct and indirect mechanisms.
TLR Expression and Signaling Is Increased
in Patients With Myelodysplastic
Syndromes (MDS), and Is Associated With
Disease Severity
The myelodysplastic syndromes (MDS) are a group of
hematopoietic stem cell disorders characterized by abnormal
hematopoiesis and a high risk of transformation to acute myeloid
leukemia (AML) (43, 44). There are ∼10,000 new cases of MDS
per year in the US, and the incidence increases with age (45).
MDS is rare in children and young adults, though it may occur
in these populations in association with inherited bone marrow
failure syndromes (46, 47). Patients with MDS suffer from
cytopenias, requiring supportive care (e.g., red blood cell and
platelet transfusions), and risk life-threatening consequences of
these cytopenias such as infections and bleeding. In addition,
about 30% of patients with MDS will progress to develop AML
(48). The prognosis of patients with MDS is determined using
the revised International Prognostic Scoring System (IPSS-R),
which considers the degree of cytopenias, bone marrow blast
percentage, and cytogenetic abnormalities (49). This score is
used to place patients into lower- and higher-risk categories,
and helps to inform their treatment. Depending on the age
of the patient, risk category, and other comorbid factors, the
treatment options include supportive care, hypomethylating
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agents, immunomodulatory drugs, and allogeneic hematopoietic
stem cell transplantation (50). Stem cell transplantation is
the only curative option, however this is often not feasible
due to patient age or other comorbid factors (51). Thus, new
therapies are needed. As discussed below, targeting of innate
immune signaling, and particularly TLRs, is an attractive new
therapeutic approach.
The pathogenesis of MDS is thought to involve a combination
of genetic mutations (particularly involving genes that regulate
RNA splicing or influence the epigenetic landscape, in addition
to variety of other oncogenes, and tumor suppressors) (52–
55), which may be induced or selected for by genotoxic insults,
inflammatory conditions, and/or aging, and hyper-activation of
innate immune signaling pathways as a result of these genetic and
epigenetic changes that contribute to HSPC senescence, impaired
differentiation and cellular death (56–59). In lower-risk MDS,
intact DNA damage checkpoints and pro-death signals lead to
the prominent intramedullary cell death characteristic of lower-
risk disease (60, 61). In contrast, the presence of mutations that
confer resistance to these damage checkpoints and pro-death
signals is characteristic of higher-risk MDS with an accelerating
clonal expansion and increased risk of transformation to acute
leukemia (62, 63). Notably, recent studies on the clonal evolution
of MDS suggest that in many cases, disease progression is non-
linear, with diverse subclones evolving in a parallel fashion to give
rise individually to the development of MDS and secondary AML
(62, 64, 65).
Regarding the contribution of hyper-activated innate immune
signaling, numerous studies have shown that TLR signaling
is enhanced in the CD34+ HSPCs of patients with MDS,
with multiple components of the pathway (TLRs themselves
or downstream effectors) either overexpressed or aberrantly
activated compared to healthy controls (66–70). Wei et al. (69)
profiled the mRNA expression of eight TLRs (TLR1-4 and TLR6-
9) in a cohort of 149 patients with MDS, and found increased
expression of TLR2 and its binding partners, TLR1 and TLR6, in
the CD34+ cells of these patients compared to healthy controls.
Notably, they showed that TLR2 expression was highest in the
lower-risk risk patients, correlating with better overall survival,
and conversely, TLR6 expression was highest in the higher-risk
patients. Zeng et al. (70) similarly found that TLR2 was more
highly expressed in the CD34+ cells of patients with lower-risk
MDS compared to healthy controls or to patients with high-
risk disease, and they noted that TLR2 expression correlated
with increased apoptosis. Further, they showed that TLR2
agonist-associated CD34+ cell death wasmediated by β-arrestin1
upregulation and histone H4 acetylation via recruitment of
P300. β-arrestin1 mRNA levels and nuclear accumulation of
β-arrestin1 protein were significantly increased in the CD34+
cells of patients with low-risk disease compared to higher-
risk MDS or healthy controls, and inhibition of β-arrestin1 in
cultured CD34+ cells mitigated TLR2 agonist-induced cell death
(70). In a smaller series of 21 patients, Maratheftis et al. (68)
reported increased expression of TLR4 in the CD34+ cells of
patients with MDS, and this expression also correlated with
cell death. In addition to these TLRs, mRNA expression of the
downstreammediator of TLR signaling, MyD88, was found to be
increased in the CD34+ cells of patients with MDS compared to
healthy controls, and inhibition of MyD88 in cultured CD34+
cells of lower-risk patients led to increased erythroid colony
formation. Of note, like the TLRs, this expression associated with
disease status, with lower-risk patients displaying higher MyD88
expression than higher-risk patients (67).
Not only are the TLRs overexpressed in MDS, but multiple
genetic abnormalities and epigenetic events in MDS have been
found to contribute to enhanced sensitivity to TLR ligands. In
patients with deletions of 5q (del(5q) MDS), for example, loss
of a copy of the micro-RNAs mir-145 and miR-146a result in
activated TLR signaling. These micro-RNAs normally inhibit the
TLR signaling intermediates TIRAP (mir-145) and TRAF6 (mir-
146a), and knockdown of these miRs or enforced expression
of TRAF6 in mouse hematopoietic stem and progenitor
cells recapitulates some of the features of human del(5q)
MDS including elevated serum IL-6 levels, megakaryocytic
dysplasia, and progression to marrow failure or acute myeloid
leukemia (71). Enhanced TRAF6 activity in del(5q) MDS is
further exacerbated by haploinsufficiency for another 5q gene,
TRAF-interacting protein with forkhead-associated domain B
(TIFAB), which normally promotes TRAF6 degradation via a
lysosome-dependent mechanism (72). TRAF6, a ubiquitin ligase,
contributes to impaired hematopoiesis and bone marrow failure
via ubiquitination of the RNA-binding protein and auxiliary
splicing factor hnRNPA1. This modification of hnRNPA1 results
in alternative splicing and reduced expression of Arhgap1, an
inhibitor of the GTP-binding Rho family protein Cdc42, which
in turn leads to aberrant hematopoiesis (73). Very recently, Muto
et al. (74) showed that TRAF6- overexpressing HSPCs have a
competitive advantage over their normal counterparts in the face
of low-dose LPS (TLR4 ligand). This advantage is dependent
upon the expression of A20 and the activation of non-canonical
NF-κB signaling, suggesting that the mechanistic basis for the
clonal advantage of MDS HSPCs involves an adaptive response
to TLR stimulation with a shift from canonical to non-canonical
NF-κB signaling.
Additionally, spliceosome mutations (e.g., involving
spliceosome components such as SF3B1, U2AF1, and SRSF2),
which are common in MDS (75), have been found to confer
sensitivity to TLR ligands by promoting the production
of activating forms of components of the TLR signaling
pathways. For example, Smith et al. (76) found that the
expression of a longer isoform of IRAK4 (IRAK4-L), which is
associated with enhanced activation of NF-kB and leukemic
transformation, is mediated by mutant forms of the splicing
factor U2 small nuclear RNA auxiliary factor 1 (U2AF1).
Similarly, Alper et al. (77–79) showed that inhibition of
spliceosome genes reduces inflammatory cytokine production
in response to TLR agonists, and conversely, expression of
MDS-associated spliceosome mutations (involving splicing
factors U2AF1, SF3B1, or SRSF2) enhances NF-κB activity
and cytokine production by K562 myeloid leukemia cells
following TLR stimulation. Mechanistically, the spliceosome
mutations alter the splicing of genes that regulate TLR signaling
and promote NF-κB activation, including MAP3K7 and
CASP8 (77).
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In addition to increased expression of TLRs and components
of the TLR signaling pathways, as well as enhanced sensitivity
to TLR ligands in the HSPCs of patients with MDS, some of
the known TLR ligands are more abundant in the bone marrow
and/or serum of individuals with MDS compared to healthy
controls. High mobility group box 1 (HMGB1), for example, a
nuclear DAMP released upon cell death that stimulates TLR2
and TLR4, is increased in the serum of patients with MDS
(80). Kam et al. (81) recently reported that HMGB1 inhibition
in cultures of an MDS cell line or primary MDS CD34+ cells
with the small molecule sivelestat reduced cellular expansion and
colony forming ability in vitro, as well as engraftment of the
MDS-L cell line into NSG mice. Further, inhibition of HMGB1
resulted in enhanced cell death, with increased expression of
p53-upregulated modulator of apoptosis (PUMA) and activation
of caspase-3. Interestingly, this inhibition also reduced the
expression of TLRs themselves in MDS CD34+ cells, suggesting
that TLR stimulation may amplify its own expression in MDS.
Besides HMGB1, the TLR4 ligands S100A8 and S100A9
are elevated in the bone marrow and blood of MDS patients
compared to controls, with the highest levels specifically found
in patients with lower-risk disease (82, 83). S100A8 and S100A9
are members of the S100 family of calcium-binding proteins that
exist as heterodimers (known as calprotectin) or homodimers,
and are expressed constitutively by myeloid lineage cells (84, 85).
These endogenous DAMPS are passively released by necrotic
cells or actively secreted by activated immune cells (86), bind to
both TLR4 and the myeloid cell receptor CD33, and contribute
to the ineffective hematopoiesis in MDS via direct and indirect
effects on HSPCs (87). S100A8 and S100A9, in addition to
playing a direct role in promoting cell death in HSPCs in MDS,
as discussed further below, expand myeloid derived suppressor
cells (MDSCs) in the bone marrow of patients with MDS
through binding to CD33. MDSCs are CD33+ Lineage- HLA-
DR- immature myeloid cells, and their frequency is significantly
increased in patients with MDS compared to healthy controls
(88, 89). Supporting a role for MDSCs and S100A9 in the
pathogenesis of MDS, S100A9 transgenic mice that overexpress
this DAMP in hematopoietic cells display an accumulation
of MDSCs with age, and develop progressive multilineage
cytopenias and dysplasias characteristic of human MDS (88).
MDSCs, which are typically distinct from the malignant clone
in MDS, contribute to the suppression of normal hematopoiesis
via the production of cytokines such as IL-10 and transforming
growth factor beta (TGFβ) (89). In addition, MDSCs can exert a
direct suppressive effect on the growth of erythroid and myeloid
progenitor cells in vitro (88), and very recent data from Cheng
et al. showed that the immune checkpoint receptor programmed
cell death protein-1 (PD-1) and its ligand programmed cell
death-ligand 1 (PD-L1) are upregulated in response to S100A9
signaling and contribute to MDSC-induced HSPC death in
MDS (90). Activated MDSCs secrete more S100A8 and S100A9
(91), thus supporting autocrine and paracrine TLR and CD33
stimulation and promoting further expansion of MSDCs and
inflammatory cytokine production.
Together, the above studies clearly establish enhanced TLR
signaling as a common feature ofMDS, particularly in the context
of lower-risk disease. The role of this enhanced TLR signaling
in the pathogenesis of the disease remains somewhat unclear,
however, and additional studies are necessary to fully elucidate
the contribution of TLR signaling to the initiation and promotion
of MDS. In addition, the etiology of increased TLR expression in
MDS is not well-understood, and further studies are warranted
to determine how TLR expression is regulated in both lower- and
higher-risk MDS HSPCs. TLR expression and signaling patterns
differ between low- and high-risk MDS, and the origin of these
differences and the roles of specific TLRs in different stages of
disease are not clear. Notably, TLR expression is induced in a
variety of cell types by inflammatory cytokines (92–94) and also
via positive feedback by TLR ligation itself (81), suggesting that
the inflammatory microenvironment may reinforce elevated TLR
expression and signaling. Finally, studies of TLR signaling in
MDS have largely focused on HSPCs, and, aside from MDSCs,
the expression of TLRs and contribution of TLR signaling in
populations outside of HSPCs to the pathogenesis of MDS is not
well-understood. One aspect of MDS pathogenesis that is clearly
influenced by TLR signaling is cell death, with accumulating data,
as discussed below, implicating this signaling in promoting the
intramedullary death of HSPCs in patients with lower-risk MDS.
TLR Signaling Promotes Cell Death in MDS
A hallmark of low-risk MDS is increased death of bone marrow
CD34+ cells (95–98), and multiple studies have implicated a
role for TLR signaling in this process. Both TLR2 and TLR4
signaling have been associated with cell death in MDS, and
recent studies demonstrate that TLR signaling promotes an
inflammatory form of programmed cell death termed pyroptosis
(11, 99, 100). Pyroptosis is mediated by the formation of
multiprotein complexes, known as the inflammasome, composed
of nucleotide-binding domain and leucine-rich repeat pattern-
recognition receptors (NLRs), most notably NOD-like receptor
pyrin domain-containing 3 (NLRP3) (101). NLRP3 assembly,
which is stimulated by DAMPs, leads to the recruitment of
the adaptor protein apoptosis-associated speck like protein
containing a CARD (PYCARD, also known as ASC), which then
form large helical fibrils that assemble into complexes referred to
as ASC specks (102–104). These specks function as a platform
for the binding and autoproteolytic activation of pro-caspase-
1, which then activates pro-IL-1β and pro-IL-18 as well as the
pore-forming protein gasdermin D (105–111). Membrane pores
created by activated gasdermin D lead to cation entry and cell
swelling, triggering pyroptotic cell death with the release of active
IL-1β, IL-18, and as well as ASC specks and other intracellular
proteins that contribute to local inflammation (112, 113).
TLR agonists such as S100A8 and S100A9, which bind
to TLR4 and CD33, stimulate inflammasome assembly, and
pyroptosis by enhancing the production of inflammasome
components, and proinflammatory cytokines such as pro-IL-
1β, and pro-IL-18. In addition, TLR agonists promote the
activation of NADPH oxidase to generate reactive oxygen
species (ROS), which contribute to inflammasome assembly
and inflammatory cytokine production (114). In a recent
study, Basiorka et al. (82) reported that markers of pyroptosis
(activated caspase-1, NLRP3, and ASC speck levels) were
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higher in the bone marrow mononuclear cells (BM-MNCs)
of patients with MDS compared to healthy controls, and
cell death was inhibited by shRNA-mediated knockdown of
NLRP3 or caspase- 1. Further, they showed that S100A9-
induced signaling activates NADPH oxidase, increasing ROS
and triggering pyroptosis and β-catenin activation in MDS
BM-MNCs, and inhibition of S100A9 using a decoy receptor
reduced transcriptional priming of pyroptosis-associated genes
(CASP1, IL-1B, IL-18, and NLRP3) and improved the colony-
forming capacity of BM-MNCs from patients with MDS. In
a follow up survey of 177 patients with MDS (115), Basiorka
et al. quantified ASC specks by flow cytometry and found
the mean percentage of peripheral blood plasma-derived ASC
specks to be significantly higher than in 29 age-matched
healthy controls (115). These findings were validated in an
additional cohort of 133 patients and 31 healthy controls,
and they found that ASC speck percentage correlated with
lower-risk disease as well as with S100A8 and S100A9 plasma
levels. These data support the idea that pyroptosis is a
prominent form of cell death in MDS, with TLR signaling-
particularly stimulation via S100A8 and S100A9- contributing to
this process.
Further implicating TLR signaling in the promotion of
pyroptotic cell death in MDS, we recently reported that loss
of TLR2 or MyD88 in the NUP98-HOXD13 (NHD13) mouse
model of MDS led to a reduction in premalignant cell death
andmore rapid leukemic transformation (116). Similar to human
MDS, the NHD13 mice (expressing the NUP98-HOXD13 fusion
from the hematopoietic Vav-1 promoter) display cytopenias,
bone marrow dysplasia, and increased HSPC cell death, and
the mice die of acute leukemia (predominately myeloid) or
bone marrow failure by about a year of life (117). Compared
to NHD13 mice; NHD13; Tlr2−/− and NHD13; MyD88−/−
mice have reduced survival and accelerated leukemogenesis,
and mechanistic evaluations showed that loss of TLR signaling
was associated with a reduction in activated caspase-1 and
decreased cell death of premalignant HSPCs. Furthermore,
we noted that while young adult NHD13 mice displayed
increased surface TLR2 expression on their bone marrow HSPCs
compared to WT littermates, this expression was markedly
reduced (or absent) on leukemic blasts, suggesting that TLR2 is
downregulated at some point during the transformation process.
This finding is consistent with the human studies showing
higher expression of TLR2 in low-risk patients compared to
FIGURE 1 | TLR signaling is enhanced in MDS. In low-risk MDS, TLR signaling is enhanced via increased expression of TLRs, increased abundance of DAMPs such
as HMGB1 and S100A8/A9, and increased sensitivity to TLR ligands. S100A8/A9 binds to TLR4 and CD33, stimulating inflammasome assembly and pyroptotic cell
death by promoting the production of inflammasome components, ROS, and proinflammatory cytokines such as IL-1β and IL-18. In addition, S100A8/A9 binding to
CD33 expands MDSCs, which contribute to the suppression of normal hematopoiesis via the production of cytokines such as IL-10 and TGFβ. Activated MDSCs
secrete more S100A8 and S100A9, thereby promoting autocrine and paracrine TLR and CD33 signaling and stimulating further expansion of MSDCs and
inflammatory cytokine production. In high-risk MDS and AML, endogenous DAMPs and MDSCs are less abundant than in low-risk MDS, and there is less cell death.
Also, expression levels of TLR2, TLR4, and MyD88 are lower than in low-risk MDS. On the other hand, expression of an activating form of IRAK4 is associated with
high-risk MDS and leukemic transformation.
Frontiers in Immunology | www.frontiersin.org 5 June 2020 | Volume 11 | Article 1236
Paracatu and Schuettpelz TLR Signaling in MDS
high-risk (69, 70), as well as the correlation between TLR2
expression and cell death (70). Together, these data suggest
that while TLR2 signaling may contribute to the death of
HSPCs- a prominent feature of low-risk disease- it may also
serve a protective role against the accumulation of premalignant
cells and ultimate transformation. It is presently unclear
what regulates TLR2 expression in the HSPCs of patients
with MDS, and how this expression is reduced in higher-
risk patients.
Targeting TLR Signaling in the Treatment
of MDS
As discussed above, multiple components of the TLR signaling
pathway are upregulated in MDS, which has prompted
enthusiasm for targeting this signaling therapeutically. A TLR2
inhibitory antibody (Tomaralimab, Opsona Therapeutics) has
now been trialed as second-line therapy for patients with lower-
risk MDS (NCT02363491) (118). In addition, a phase I study
of a novel small molecule inhibitor of IRAK4 is currently
enrolling patients with high-riskMDS and AML (NCT04278768)
(119). Of note, enhanced TLR signaling is largely specific
to lower-risk MDS, where it promotes cell death, and the
effects of TLR signaling and the potential consequences of
its inhibition in higher-risk patients is not clear. That said,
certain elements of TLR signaling, such as expression of the
activating form of IRAK4 (IRAK4-L), are more characteristic
of high-risk MDS and progression to AML (76). Thus, not all
TLR signaling may be equal in MDS, with certain TLRs or
signaling components conferring different effects in different
disease contexts. These nuances regarding the role of TLR
signaling in both lower- and higher-risk MDS warrant further
study, and will help inform which patients might benefit
from modulation of TLR signaling, as well as identify the
components of this signaling pathway that represent the best
therapeutic targets.
Finally, while inhibition of TLR signaling has been the general
strategy for MDS, multiple studies suggest that stimulation of
this signaling may have therapeutic efficacy in AML, with TLR
agonists promoting the death and differentiation of myeloid
blasts (120–126). For example, S100A9 was found to induce cell
differentiation and growth arrest and prolong survival in a mouse
model of AML, and mechanistic studies showed that S100A9
induced this differentiation in AML cells via S100A9 binding
to TLR4 and activation of ERK1/2 and JNK signaling pathways
(125). Eriksson et al. (124) demonstrated that the TLR1/2 agonist
PAM3CSK4 induces p38-dependent apoptosis and NF-κB-
dependent differentiation of both murine and primary human
AML cells (124). Similarly, Ignatz-Hoover et al. (123) found
that TLR8 activation promotes AML differentiation and growth
inhibition in aMyD88 and p38-dependent fashion. Finally, TLR7
stimulation with imiquimod inhibited proliferation, upregulated
myeloid differentiation markers, and induced apoptosis in AML
cell lines (127).
In addition to directly promoting AML cell death and
differentiation, TLR agonists have also been considered for
use as anti-tumor agents for their indirect effects on leukemia
cells via promotion of the natural immune response to
these cells (128–130). For example, incubation of primary
AML cells with the TLR7/8 agonist R-848 led to increased
expression of MHC molecules, proinflammatory cytokine
production, and enhanced stimulation of allogeneic NK,
NKT, and T cells (128), and loading of AML cells with
the TLR3 agonist polyriboinosinic polyribocytidylic acid
[poly(I:C)] led to increased MHC expression, apoptosis, and
proinflammatory cytokine production, and enhanced the
maturation and activation of dendritic cells after their uptake
(125, 128, 129). Thus, the role of TLR signaling in MDS appears
to be context-dependent, and the clinical application of agents
that modulate TLR signaling should take into account the
disease status, likelihood of progression to AML, and the
particular components of the TLR signaling machinery that
are activated in a given patient. Finally, TLR-targeted therapies
alone may not eradicate MDS, but may be a useful component
of therapy to optimize normal blood cell production and slow
disease progression.
SUMMARY AND FUTURE DIRECTIONS
Enhanced innate immune signaling, and in particular TLR
signaling, is a common feature of MDS. The etiology of
this TLR signaling upregulation is multifactorial, involving
increased expression of TLRs and downstream signaling
components, enhanced sensitivity to TLR stimulation, and
increased availability of TLR ligands in the bone marrow
and blood of patients with MDS. In many cases, the
mechanism of TLR upregulation is not clear. Furthermore,
TLR expression differs between low- and high-risk patients,
suggesting that the role of TLR signaling may change
as MDS disease progresses (Figure 1). Further studies are
necessary to determine the contribution of specific TLRs to
disease pathogenesis, as well as to understand how their
expression is regulated in both lower- and higher-risk MDS.
Finally, the contribution of TLR signaling in cell type(s)
aside from CD34+ HSPCs to the ineffective hematopoiesis
and/or leukemic progression is not well-understood, and a
more comprehensive study of how TLR signaling is altered
throughout the bone marrow in patients with MDS is warranted.
Ultimately, these studies will help to inform the development
of improved TLR signaling-targeted therapies for the treatment
of MDS.
AUTHOR CONTRIBUTIONS
LP and LS wrote this review manuscript and generated the figure
together. All authors contributed to the article and approved the
submitted version.
FUNDING
This work was supported by the National Institutes of Health
grant R01HL134896 (LS), the Children’s Discovery Institute of
Washington University, and St. Louis Children’s Hospital (LS).
Frontiers in Immunology | www.frontiersin.org 6 June 2020 | Volume 11 | Article 1236
Paracatu and Schuettpelz TLR Signaling in MDS
REFERENCES
1. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR
signalling. Mediators Inflamm. (2010) 2010. doi: 10.1155/2010/672395
2. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate
immune response. Nature. (2000) 406:782–7. doi: 10.1038/35021228
3. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The
dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the
potent antifungal response in Drosophila adults. Cell. (1996) 86:973–
83. doi: 10.1016/S0092-8674(00)80172-5
4. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of
the drosophila toll protein signals activation of adaptive immunity. Nature.
(1997). 388:394–7. doi: 10.1038/41131
5. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of
human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci
USA. (1998) 95:588–93. doi: 10.1073/pnas.95.2.588
6. Chaudhary PM, Ferguson C, Nguyen V, Nguyen O, Massa HF, Eby M, et al.
Cloning and characterization of two Toll/Interleukin-1 receptor-like genes
TIL3 and TIL4: evidence for a multi-gene receptor family in humans. Blood.
(1998) 91:4020–7. doi: 10.1182/blood.V91.11.4020.411a44_4020_4027
7. Nagai Y, Garrett KP, Ohta S, Bahrun U, Kouro T, Akira S,
et al. Toll-like receptors on hematopoietic progenitor cells
stimulate innate immune system replenishment. Immunity. (2006)
24:801–12. doi: 10.1016/j.immuni.2006.04.008
8. Herman AC, Monlish DA, Romine MP, Bhatt ST, Zippel S, Schuettpelz LG.
Systemic TLR2 agonist exposure regulates hematopoietic stem cells via cell-
autonomous and cell-non-autonomous mechanisms. Blood Cancer J. (2016)
6:e437. doi: 10.1038/bcj.2016.45
9. Megias J, Yanez A, Moriano S, O’Connor JE, Gozalbo D, Gil ML. Direct Toll-
like receptor-mediated stimulation of hematopoietic stem and progenitor
cells occurs in vivo and promotes differentiation toward macrophages. Stem
Cells. (2012) 30:1486–95. doi: 10.1002/stem.1110
10. Esplin BL, Shimazu T, Welner RS, Garrett KP, Nie L, Zhang Q, et al. Chronic
exposure to a TLR ligand injures hematopoietic stem cells. J Immunol. (2011)
186:5367–75. doi: 10.4049/jimmunol.1003438
11. Sallman DA, List A. The central role of inflammatory signaling in
the pathogenesis of myelodysplastic syndromes. Blood. (2019) 133:1039–
48. doi: 10.1182/blood-2018-10-844654
12. Chuang TH, Ulevitch RJ. Cloning and characterization of a sub-family of
human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw.
(2000) 11:372–8.
13. Du X, Poltorak A, Wei Y, Beutler B. Three novel mammalian toll-like
receptors: gene structure, expression, and evolution. Eur Cytokine Netw.
(2000) 11:362–71.
14. Takeuchi O, Kawai T, Sanjo H, Copeland NG, Gilbert DJ, Jenkins NA, et al.
TLR6: a novel member of an expanding toll-like receptor family. Gene.
(1999) 231:59–65. doi: 10.1016/S0378-1119(99)00098-0
15. Chuang T, Ulevitch RJ. Identification of hTLR10: a novel human Toll-like
receptor preferentially expressed in immune cells. Biochim Biophys Acta.
(2001) 1518:157–61. doi: 10.1016/S0167-4781(00)00289-X
16. O’Neill LA, Golenbock D, Bowie AG. The history of Toll-like
receptors - redefining innate immunity. Nat Rev Immunol. (2013)
13:453–60. doi: 10.1038/nri3446
17. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors
and differential regulation of Toll-like receptor mRNAs in leukocytes in
response to microbes, their products, and cytokines. J Immunol. (2002)
168:554–61. doi: 10.4049/jimmunol.168.2.554
18. Fitzner N, Clauberg S, Essmann F, Liebmann J, Kolb-Bachofen V.
Human skin endothelial cells can express all 10 TLR genes and
respond to respective ligands. Clin Vaccine Immunol. (2008) 15:138–
46. doi: 10.1128/CVI.00257-07
19. Crack PJ, Bray PJ. Toll-like receptors in the brain and their
potential roles in neuropathology. Immunol Cell Biol. (2007)
85:476–80. doi: 10.1038/sj.icb.7100103
20. Schmid MA, Takizawa H, Baumjohann DR, Saito Y, Manz MG. Bone
marrow dendritic cell progenitors sense pathogens via Toll-like receptors
and subsequently migrate to inflamed lymph nodes. Blood. (2011) 118:4829–
40. doi: 10.1182/blood-2011-03-344960
21. Oliveira-Nascimento L, Massari P,Wetzler LM. The role of TLR2 in infection
and immunity. Front Immunol. (2012) 3:79. doi: 10.3389/fimmu.2012.00079
22. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, et al. Cutting
edge: role of Toll-like receptor 1 in mediating immune response to microbial
lipoproteins. J Immunol. (2002) 169:10–4. doi: 10.4049/jimmunol.169.1.10
23. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, et al.
Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol.
(2001) 13:933–40. doi: 10.1093/intimm/13.7.933
24. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al.
Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling
pathway. Science. (2003) 301:640–3. doi: 10.1126/science.1087262
25. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda
K, et al. Cutting edge: a novel Toll/IL-1 receptor domain-
containing adapter that preferentially activates the IFN-beta
promoter in the Toll-like receptor signaling. J Immunol. (2002)
169:6668–72. doi: 10.4049/jimmunol.169.12.6668
26. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S,
et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling
pathways. Mol Cell. (1998) 2:253–8. doi: 10.1016/S1097-2765(00)80136-7
27. Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J. Inhibition of
interleukin 1 receptor/Toll-like receptor signaling through the alternatively
spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp
Med. (2003) 197:263–8. doi: 10.1084/jem.20021790
28. Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-
IRAK2 complex in TLR/IL-1R signalling. Nature. (2010) 465:885–
90. doi: 10.1038/nature09121
29. Motshwene PG, Moncrieffe MC, Grossmann JG, Kao C, Ayaluru M,
Sandercock AM, et al. An oligomeric signaling platform formed by the Toll-
like receptor signal transducers MyD88 and IRAK-4. J Biol Chem. (2009)
284:25404–11. doi: 10.1074/jbc.M109.022392
30. LandstromM. The TAK1-TRAF6 signalling pathway. Int J Biochem Cell Biol.
(2010) 42:585–9. doi: 10.1016/j.biocel.2009.12.023
31. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. TICAM-1,
an adaptor molecule that participates in Toll-like receptor 3-mediated
interferon-beta induction. Nat Immunol. (2003) 4:161–7. doi: 10.1038/ni886
32. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT,
et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling
pathway. Nat Immunol. (2003) 4:491–6. doi: 10.1038/ni921
33. Sato S, Sugiyama M, Yamamoto M, Watanabe Y, Kawai T, Takeda K, et al.
Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF)
associates with TNF receptor-associated factor 6 and TANK-binding kinase
1, and activates two distinct transcription factors, NF-kappa B and IFN-
regulatory factor-3, in the Toll-like receptor signaling. J Immunol. (2003)
171:4304–10. doi: 10.4049/jimmunol.171.8.4304
34. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO, et al. Identification
of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature.
(2003) 424:743–8. doi: 10.1038/nature01889
35. Takizawa H, Boettcher S, Manz MG. Demand-adapted regulation of early
hematopoiesis in infection and inflammation. Blood. (2012) 119:2991–
3002. doi: 10.1182/blood-2011-12-380113
36. Welner RS, Pelayo R, Nagai Y, Garrett KP, Wuest TR, Carr DJ,
et al. Lymphoid precursors are directed to produce dendritic cells as a
result of TLR9 ligation during herpes infection. Blood. (2008) 112:3753–
61. doi: 10.1182/blood-2008-04-151506
37. He Q, Zhang C, Wang L, Zhang P, Ma D, Lv J, et al. Inflammatory signaling
regulates hematopoietic stem and progenitor cell emergence in vertebrates.
Blood. (2015) 125:1098–6. doi: 10.1182/blood-2014-09-601542
38. Espin-Palazon R, Stachura DL, Campbell CA, Garcia-Moreno D, Del Cid N,
Kim AD, et al. Proinflammatory signaling regulates hematopoietic stem cell
emergence. Cell. (2014) 159:1070–85. doi: 10.1016/j.cell.2014.10.031
39. Ichii M, Shimazu T, Welner RS, Garrett KP, Zhang Q, Esplin
BL, et al. Functional diversity of stem and progenitor cells
with B-lymphopoietic potential. Immunol Rev. (2010) 237:10–
21. doi: 10.1111/j.1600-065X.2010.00933.x
40. Schuettpelz LG, Borgerding JN, Christopher MJ, Gopalan PK, Romine MP,
Herman AC, et al. G-CSF regulates hematopoietic stem cell activity, in
part, through activation of Toll-like receptor signaling. Leukemia. (2014)
28:1851–60 doi: 10.1038/leu.2014.68
Frontiers in Immunology | www.frontiersin.org 7 June 2020 | Volume 11 | Article 1236
Paracatu and Schuettpelz TLR Signaling in MDS
41. Takizawa H, Fritsch K, Kovtonyuk LV, Saito Y, Yakkala C, Jacobs K, et al.
Pathogen-induced TLR4-TRIF innate immune signaling in hematopoietic
stem cells promotes proliferation but reduces competitive fitness. Cell Stem
Cell. (2017) 21:225–40 e5. doi: 10.1016/j.stem.2017.06.013
42. Zhang H, Rodriguez S, Wang L, Wang S, Serezani H, Kapur R, et al.
Sepsis induces hematopoietic stem cell exhaustion and myelosuppression
through distinct contributions of TRIF and MYD88. Stem Cell Rep. (2016)
6:940–56. doi: 10.1016/j.stemcr.2016.05.002
43. Jacobs A. Myelodysplastic syndromes: pathogenesis, functional
abnormalities, and clinical implications. J Clin Pathol. (1985)
38:1201–17. doi: 10.1136/jcp.38.11.1201
44. Galton DA. The myelodysplastic syndromes. Clin Lab Haematol. (1984)
6:99–112. doi: 10.1111/j.1365-2257.1984.tb00532.x
45. Al-Kali A, Zblewski D, Foran JM, Patnaik MS, Larrabee BR, Gangat N, et al.
Outcome of myelodysplastic syndromes over time in the United States: a
national cancer data base study from 2004-2013. Mayo Clin Proc. (2019)
94:1467–74. doi: 10.1016/j.mayocp.2019.02.029
46. Glaubach T, Robinson LJ, Corey SJ. Pediatric myelodysplastic
syndromes: they do exist! J Pediatr Hematol Oncol. (2014)
36:1–7. doi: 10.1097/MPH.0000000000000046
47. Schwartz JR, Ma J, Lamprecht T, Walsh M, Wang S, Bryant V, et al. The
genomic landscape of pediatric myelodysplastic syndromes. Nat Commun.
(2017) 8:1557. doi: 10.1038/s41467-017-01590-5
48. Montalban-Bravo G, Garcia-Manero G. Myelodysplastic syndromes: 2018
update on diagnosis, risk-stratification and management. Am J Hematol.
(2018) 93:129–47. doi: 10.1002/ajh.24930
49. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F,
et al. Revised international prognostic scoring system for myelodysplastic
syndromes. Blood. (2012) 120:2454–65. doi: 10.1182/blood-2012-03-420489
50. Steensma DP. Myelodysplastic syndromes current treatment algorithm
(2018) Blood Cancer J. (2018) 8:47. doi: 10.1038/s41408-018-0085-4
51. Bhatt VR, Steensma DP. Hematopoietic cell transplantation
for myelodysplastic syndromes. J Oncol Pract. (2016) 12:786–
92. doi: 10.1200/JOP.2016.015214
52. Raza A, Galili N. The genetic basis of phenotypic heterogeneity
in myelodysplastic syndromes. Nat Rev Cancer. (2012) 12:849–
59. doi: 10.1038/nrc3321
53. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al.
Landscape of genetic lesions in 944 patients withmyelodysplastic syndromes.
Leukemia. (2014) 28:241–7. doi: 10.1038/leu.2013.336
54. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, et al. Recurrent
DNMT3Amutations in patients withmyelodysplastic syndromes. Leukemia.
(2011) 25:1153–8. doi: 10.1038/leu.2011.44
55. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, et al.
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic
syndromes. Nat Genet. (2011) 44:53–7. doi: 10.1038/ng.1031
56. Chamseddine AN, Jabbour E, Kantarjian HM, Bohannan ZS, Garcia-
Manero G. Unraveling myelodysplastic syndromes: current knowledge and
future directions. Curr Oncol Rep. (2016) 18:4. doi: 10.1007/s11912-015-
0489-2
57. Varney ME, Melgar K, Niederkorn M, Smith MA, Barreyro L, Starczynowski
DT. Deconstructing innate immune signaling inmyelodysplastic syndromes.
Exp Hematol. (2015) 43:587–98. doi: 10.1016/j.exphem.2015.05.016
58. Barreyro L, Chlon TM, Starczynowski DT. Chronic immune
response dysregulation in MDS pathogenesis. Blood. (2018)
132:1553–60. doi: 10.1182/blood-2018-03-784116
59. Ganan-Gomez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-
Calvo M, et al. Deregulation of innate immune and inflammatory
signaling in myelodysplastic syndromes. Leukemia. (2015) 29:1458–
69. doi: 10.1038/leu.2015.69
60. Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the
progression of myelodysplastic syndrome. Exp Hematol. (2007) 35:1739–
46. doi: 10.1016/j.exphem.2007.09.007
61. Tsoplou P, Kouraklis-Symeonidis A, Thanopoulou E, Zikos P, Orphanos
V, Zoumbos NC. Apoptosis in patients with myelodysplastic syndromes:
differential involvement of marrow cells in ’good’ versus ’poor’ prognosis
patients and correlation with apoptosis-related genes. Leukemia. (1999)
13:1554–63. doi: 10.1038/sj.leu.2401538
62. Chen J, Kao YR, Sun D, Todorova TI, Reynolds D, Narayanagari SR, et al.
Myelodysplastic syndrome progression to acute myeloid leukemia at the
stem cell level. Nat Med. (2019) 25:103–10. doi: 10.1038/s41591-018-0267-4
63. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S,
Pagliuca A. The role of apoptosis, proliferation, and the Bcl-
2-related proteins in the myelodysplastic syndromes and acute
myeloid leukemia secondary to MDS. Blood. (2000) 96:3932–
8. doi: 10.1182/blood.V96.12.3932.h8003932_3932_3938
64. Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki
H, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat
Genet. (2017) 49:204–12. doi: 10.1038/ng.3742
65. da Silva-Coelho P, Kroeze LI, Yoshida K, Koorenhof-Scheele TN, Knops R,
van de Locht LT, et al. Clonal evolution in myelodysplastic syndromes. Nat
Commun. (2017) 8:15099. doi: 10.1038/ncomms15099
66. Kuninaka N, Kurata M, Yamamoto K, Suzuki S, Umeda S, Kirimura S, et al.
Expression of Toll-like receptor 9 in bone marrow cells of myelodysplastic
syndromes is down-regulated during transformation to overt leukemia. Exp
Mol Pathol. (2010) 88:293–8. doi: 10.1016/j.yexmp.2010.01.009
67. Dimicoli S, Wei Y, Bueso-Ramos C, Yang H, Dinardo C, Jia Y, et al.
Overexpression of the Toll-Like Receptor (TLR) signaling adaptor MYD88,
but lack of genetic mutation, in myelodysplastic syndromes. PLoS ONE.
(2013) 8:e71120. doi: 10.1371/journal.pone.0071120
68. Maratheftis CI, Andreakos E, Moutsopoulos HM, Voulgarelis M. Toll-like
receptor-4 is up-regulated in hematopoietic progenitor cells and contributes
to increased apoptosis inmyelodysplastic syndromes. Clin Cancer Res. (2007)
13:1154–60. doi: 10.1158/1078-0432.CCR-06-2108
69. Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, et al.
Toll-like receptor alterations inmyelodysplastic syndrome. Leukemia. (2013)
27:1832–40. doi: 10.1038/leu.2013.180
70. Zeng Q, Shu J, Hu Q, Zhou SH, Qian YM, HuMH, et al. Apoptosis in human
myelodysplastic syndrome CD34+ cells is modulated by the upregulation of
TLRs and histone H4 acetylation via a beta-arrestin 1 dependent mechanism.
Exp Cell Res. (2016) 340:22–31. doi: 10.1016/j.yexcr.2015.12.008
71. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R,
Muranyi A, et al. Identification of miR-145 and miR-146a as mediators of the
5q- syndrome phenotype. Nat Med. (2010) 16:49–58. doi: 10.1038/nm.2054
72. Varney ME, Niederkorn M, Konno H, Matsumura T, Gohda J, Yoshida
N, et al. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through
derepression of Toll-like receptor-TRAF6 signaling. J Exp Med. (2015)
212:1967–85. doi: 10.1084/jem.20141898
73. Fang J, Bolanos LC, Choi K, Liu X, Christie S, Akunuru S,
et al. Ubiquitination of hnRNPA1 by TRAF6 links chronic innate
immune signaling with myelodysplasia. Nat Immunol. (2017)
18:236–45. doi: 10.1038/ni.3654
74. Muto T, Walker CS, Choi K, Hueneman K, Smith MA, Gul Z, et al. Adaptive
response to inflammation contributes to sustained myelopoiesis and confers
a competitive advantage in myelodysplastic syndrome HSCs. Nat Immunol.
(2020) 21:535–45. doi: 10.1038/s41590-020-0663-z
75. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R,
et al. Frequent pathway mutations of splicing machinery in myelodysplasia.
Nature. (2011) 478:64–9. doi: 10.1038/nature10496
76. Smith MA, Choudhary GS, Pellagatti A, Choi K, Bolanos LC, Bhagat TD,
et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate
innate immune pathways in myeloid malignancies. Nat Cell Biol. (2019)
21:640–50. doi: 10.1038/s41556-019-0314-5
77. Pollyea DA, Harris C, Rabe JL, Hedin BR, De Arras L, Katz S,
et al. Myelodysplastic syndrome-associated spliceosome gene mutations
enhance innate immune signaling. Haematologica. (2019) 104:e388–
92. doi: 10.3324/haematol.2018.214155
78. De Arras L, Alper S. Limiting of the innate immune response by SF3A-
dependent control of MyD88 alternative mRNA splicing. PLoS Genet. (2013)
9:e1003855. doi: 10.1371/journal.pgen.1003855
79. O’Connor BP, Danhorn T, De Arras L, Flatley BR, Marcus RA,
Farias-Hesson E, et al. Regulation of toll-like receptor signaling
by the SF3a mRNA splicing complex. PLoS Genet. (2015)
11:e1004932. doi: 10.1371/journal.pgen.1004932
80. Velegraki M, Papakonstanti E, Mavroudi I, Psyllaki M, Tsatsanis C,
Oulas A, et al. Impaired clearance of apoptotic cells leads to HMGB1
Frontiers in Immunology | www.frontiersin.org 8 June 2020 | Volume 11 | Article 1236
Paracatu and Schuettpelz TLR Signaling in MDS
release in the bone marrow of patients with myelodysplastic syndromes
and induces TLR4-mediated cytokine production. Haematologica. (2013)
98:1206–15. doi: 10.3324/haematol.2012.064642
81. Kam AYF, Piryani SO, McCall CM, Park HS, Rizzieri DA, Doan
PL. Targeting High Mobility Group Box-1 (HMGB1) promotes cell
death in myelodysplastic syndrome. Clin Cancer Res. (2019) 25:4155–
67. doi: 10.1158/1078-0432.CCR-18-3517
82. Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson
J, Zhang L, et al. The NLRP3 inflammasome functions as a
driver of the myelodysplastic syndrome phenotype. Blood. (2016)
128:2960–75. doi: 10.1182/blood-2016-07-730556
83. Giudice V,Wu Z, Kajigaya S, Fernandez IbanezMDP, Rios O, Cheung F, et al.
Circulating S100A8 and S100A9 protein levels in plasma of patients with
acquired aplastic anemia and myelodysplastic syndromes. Cytokine. (2019)
113:462–5. doi: 10.1016/j.cyto.2018.06.025
84. Zwadlo G, Bruggen J, Gerhards G, Schlegel R, Sorg C. Two calcium-binding
proteins associated with specific stages of myeloid cell differentiation are
expressed by subsets of macrophages in inflammatory tissues. Clin Exp
Immunol. (1988) 72:510–5.
85. Lagasse E, Clerc RG. Cloning and expression of two human genes encoding
calcium-binding proteins that are regulated during myeloid differentiation.
Mol Cell Biol. (1988) 8:2402–10. doi: 10.1128/MCB.8.6.2402
86. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA,
et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor
4, promoting lethal, endotoxin-induced shock. Nat Med. (2007) 13:1042–
9. doi: 10.1038/nm1638
87. Zambetti NA, Ping Z, Chen S, Kenswil KJG, Mylona MA, Sanders MA, et al.
Mesenchymal inflammation drives genotoxic stress in hematopoietic stem
cells and predicts disease evolution in human pre-leukemia. Cell Stem Cell.
(2016) 19:613–27. doi: 10.1016/j.stem.2016.08.021
88. Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, et al. Induction
of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest. (2013)
123:4595–611. doi: 10.1172/JCI67580
89. Kittang AO, Kordasti S, Sand KE, Costantini B, Kramer AM, Perezabellan P,
et al. Expansion of myeloid derived suppressor cells correlates with number
of T regulatory cells and disease progression in myelodysplastic syndrome.
Oncoimmunology. (2016) 5:e1062208. doi: 10.1080/2162402X.2015.1062208
90. Cheng P, Eksioglu EA, Chen X, Kandell W, Le Trinh T, Cen L, et al.
S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective
hematopoiesis in myelodysplastic syndromes. Leukemia. (2019) 33:2034–
46. doi: 10.1038/s41375-019-0397-9
91. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg
S, Srikrishna G. Proinflammatory S100 proteins regulate the
accumulation of myeloid-derived suppressor cells. J Immunol. (2008)
181:4666–75. doi: 10.4049/jimmunol.181.7.4666
92. Diesel B, Ripoche N, Risch RT, Tierling S, Walter J, Kiemer
AK. Inflammation-induced up-regulation of TLR2 expression in
human endothelial cells is independent of differential methylation
in the TLR2 promoter CpG island. Innate Immun. (2012)
18:112–23. doi: 10.1177/1753425910394888
93. Fan J, Frey RS, Malik AB. TLR4 signaling induces TLR2 expression in
endothelial cells via neutrophil NADPH oxidase. J Clin Invest. (2003)
112:1234–43. doi: 10.1172/JCI18696
94. O’Mahony DS, PhamU, Iyer R, Hawn TR, LilesWC. Differential constitutive
and cytokine-modulated expression of human Toll-like receptors in primary
neutrophils, monocytes, and macrophages. Int J Med Sci. (2008) 5:1–
8. doi: 10.7150/ijms.5.1
95. Shetty V, Hussaini S, Broady-Robinson L, Allampallam K, Mundle S,
Borok R, et al. Intramedullary apoptosis of hematopoietic cells in
myelodysplastic syndrome patients can be massive: apoptotic cells recovered
from high-density fraction of bone marrow aspirates. Blood. (2000) 96:1388–
92. doi: 10.1182/blood.V96.4.1388.h8001388_1388_1392
96. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, et al. Apoptosis
in bone marrow biopsy samples involving stromal and hematopoietic cells
in 50 patients with myelodysplastic syndromes. Blood. (1995) 86:268–
76. doi: 10.1182/blood.V86.1.268.bloodjournal861268
97. Huh YO, Jilani I, Estey E, Giles F, Kantarjian H, Freireich E, et al. More
cell death in refractory anemia with excess blasts in transformation than in
acute myeloid leukemia. Leukemia. (2002) 16:2249–52. doi: 10.1038/sj.leu.
2402704
98. Bogdanovic AD, Trpinac DP, Jankovic GM, Bumbasirevic VZ, Obradovic M,
Colovic MD. Incidence and role of apoptosis in myelodysplastic syndrome:
morphological and ultrastructural assessment. Leukemia. (1997) 11:656–
9. doi: 10.1038/sj.leu.2400640
99. Sallman DA, Cluzeau T, Basiorka AA, List A. Unraveling the pathogenesis of
MDS: the NLRP3 inflammasome and pyroptosis drive the MDS phenotype.
Front Oncol. (2016) 6:151. doi: 10.3389/fonc.2016.00151
100. Wolf D, Latz E. ASC specks: a biomarker for myelodysplastic syndromes?
Lancet Haematol. (2018) 5:e379–e80. doi: 10.1016/S2352-3026(18)30113-3
101. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell
death and inflammation. Nat Rev Microbiol. (2009) 7:99–
109. doi: 10.1038/nrmicro2070
102. Lu A, Magupalli VG, Ruan J, Yin Q, Atianand MK, Vos MR, et al.
Unified polymerization mechanism for the assembly of ASC-dependent
inflammasomes. Cell. (2014) 156:1193–206. doi: 10.1016/j.cell.2014.02.008
103. Fernandes-Alnemri T, Wu J, Yu JW, Datta P, Miller B, Jankowski W, et al.
The pyroptosome: a supramolecular assembly of ASC dimers mediating
inflammatory cell death via caspase-1 activation. Cell Death Differ. (2007)
14:1590–604. doi: 10.1038/sj.cdd.4402194
104. Hoss F, Rodriguez-Alcazar JF, Latz E. Assembly and regulation of ASC
specks. Cell Mol Life Sci. (2017) 74:1211–29. doi: 10.1007/s00018-016-2396-6
105. DickMS, Sborgi L, Ruhl S, Hiller S, Broz P. ASC filament formation serves as
a signal amplification mechanism for inflammasomes. Nat Commun. (2016)
7:11929. doi: 10.1038/ncomms11929
106. Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD
by inflammatory caspases determines pyroptotic cell death. Nature. (2015)
526:660–5. doi: 10.1038/nature15514
107. Fantuzzi G, Dinarello CA. Interleukin-18 and interleukin-1 beta: two
cytokine substrates for ICE (caspase-1). J Clin Immunol. (1999) 19:1–11.
108. Kostura MJ, Tocci MJ, Limjuco G, Chin J, Cameron P, Hillman
AG, et al. Identification of a monocyte specific pre-interleukin 1
beta convertase activity. Proc Natl Acad Sci USA. (1989) 86:5227–
31. doi: 10.1073/pnas.86.14.5227
109. Black RA, Kronheim SR, Sleath PR. Activation of interleukin-
1 beta by a co-induced protease. FEBS Lett. (1989) 247:386–
90. doi: 10.1016/0014-5793(89)81376-6
110. Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A,
et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-
induced IFN-gamma production. Nature. (1997) 386:619–23. doi: 10.1038/
386619a0
111. Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA, et al. Activation of
interferon-gamma inducing factor mediated by interleukin-1beta converting
enzyme. Science. (1997) 275:206–9. doi: 10.1126/science.275.5297.206
112. Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, et al. Inflammasome-
activated gasdermin D causes pyroptosis by forming membrane pores.
Nature. (2016) 535:153–8. doi: 10.1038/nature18629
113. Sborgi L, Ruhl S, Mulvihill E, Pipercevic J, Heilig R, Stahlberg H, et al.
GSDMDmembrane pore formation constitutes themechanism of pyroptotic
cell death. EMBO J. (2016) 35:1766–78. doi: 10.15252/embj.201694696
114. Simard JC, Cesaro A, Chapeton-Montes J, Tardif M, Antoine F, Girard
D, et al. S100A8 and S100A9 induce cytokine expression and regulate the
NLRP3 inflammasome via ROS-dependent activation of NF-kappaB(1.).
PLoS ONE. (2013) 8:e72138. doi: 10.1371/journal.pone.0072138
115. Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore
AF, Vincelette ND, Ward GA, et al. Assessment of ASC specks
as a putative biomarker of pyroptosis in myelodysplastic
syndromes: an observational cohort study. Lancet Haematol. (2018)
5:e393–402. doi: 10.1016/S2352-3026(18)30109-1
116. Monlish DA, Bhatt ST, Duncavage EJ, Greenberg ZJ, Keller JL, Romine
MP, et al. Loss of Toll-like receptor 2 results in accelerated leukemogenesis
in the NUP98-HOXD13 mouse model of MDS. Blood. (2018) 131:1032–
5. doi: 10.1182/blood-2017-08-801944
117. Lin YW, Slape C, Zhang Z, Aplan PD. NUP98-HOXD13
transgenic mice develop a highly penetrant, severe myelodysplastic
syndrome that progresses to acute leukemia. Blood. (2005)
106:287–95. doi: 10.1182/blood-2004-12-4794
Frontiers in Immunology | www.frontiersin.org 9 June 2020 | Volume 11 | Article 1236
Paracatu and Schuettpelz TLR Signaling in MDS
118. Gil-Perez A, Montalban-Bravo G. Management of myelodysplastic
syndromes after failure of response to hypomethylating agents. Ther Adv
Hematol. (2019) 10:2040620719847059. doi: 10.1177/2040620719847059
119. McElroyWT. Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors:
an updated patent review (2016-2018). Expert Opin Ther Pat. (2019) 29:243–
59. doi: 10.1080/13543776.2019.1597850
120. Nourizadeh M, Masoumi F, Memarian A, Alimoghaddam K, Moazzeni
SM, Hadjati J. Synergistic effect of Toll-like receptor 4 and 7/8 agonists is
necessary to generate potent blast-derived dendritic cells in Acute Myeloid
Leukemia. Leuk Res. (2012) 36:1193–9. doi: 10.1016/j.leukres.2012.04.007
121. Nourizadeh M, Masoumi F, Memarian A, Alimoghaddam K, Moazzeni SM,
Yaghmaie M, et al. In vitro induction of potent tumor-specific cytotoxic T
lymphocytes using TLR agonist-activated AML-DC. Target Oncol. (2014)
9:225–37. doi: 10.1007/s11523-013-0285-6
122. Lehner M, Bailo M, Stachel D, Roesler W, Parolini O, Holter W. Caspase-
8 dependent apoptosis induction in malignant myeloid cells by TLR
stimulation in the presence of IFN-alpha. Leuk Res. (2007) 31:1729–
35. doi: 10.1016/j.leukres.2007.05.001
123. Ignatz-Hoover JJ, Wang H, Moreton SA, Chakrabarti A, Agarwal MK, Sun
K, et al. The role of TLR8 signaling in acute myeloid leukemia differentiation.
Leukemia. (2015) 29:918–26. doi: 10.1038/leu.2014.293
124. Eriksson M, Pena-Martinez P, Ramakrishnan R, Chapellier M, Hogberg C,
Glowacki G, et al. Agonistic targeting of TLR1/TLR2 induces p38 MAPK-
dependent apoptosis and NFkappaB-dependent differentiation of AML cells.
Blood Adv. (2017) 1:2046–57. doi: 10.1182/bloodadvances.2017006148
125. Laouedj M, Tardif MR, Gil L, Raquil MA, Lachhab A, Pelletier M, et al.
S100A9 induces differentiation of acute myeloid leukemia cells through
TLR4. Blood. (2017) 129:1980–90. doi: 10.1182/blood-2016-09-738005
126. Okamoto M, Hirai H, Taniguchi K, Shimura K, Inaba T, Shimazaki C, et al.
Toll-like receptors (TLRs) are expressed by myeloid leukaemia cell lines, but
fail to trigger differentiation in response to the respective TLR ligands. Br J
Haematol. (2009) 147:585–7. doi: 10.1111/j.1365-2141.2009.07858.x
127. Villamon E, Gonzalez-Fernandez J, Such E, Cervera JV, Gozalbo
D, Luisa Gil M. Imiquimod inhibits growth and induces
differentiation of myeloid leukemia cell lines. Cancer Cell Int. (2018)
18:15. doi: 10.1186/s12935-018-0515-1
128. Smits EL, Cools N, Lion E, Van Camp K, Ponsaerts P, Berneman ZN,
et al. The Toll-like receptor 7/8 agonist resiquimod greatly increases
the immunostimulatory capacity of human acute myeloid leukemia cells.
Cancer Immunol Immunother. (2010) 59:35–46. doi: 10.1007/s00262-009-
0721-8
129. Smits EL, Ponsaerts P, Van de Velde AL, Van Driessche A, Cools N, Lenjou
M, et al. Proinflammatory response of human leukemic cells to dsRNA
transfection linked to activation of dendritic cells. Leukemia. (2007) 21:1691–
9. doi: 10.1038/sj.leu.2404763
130. Zhong R, Li H, Messer K, Lane TA, Zhou J, Ball ED. Augmentation of
autologous T cell reactivity with acute myeloid leukemia (AML) blasts by
Toll-like receptor (TLR) agonists. Cancer Immunol Immunother. (2015)
64:737–44. doi: 10.1007/s00262-015-1680-x
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Paracatu and Schuettpelz. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 10 June 2020 | Volume 11 | Article 1236
